Impurities in drugs V: Meprobamate

Area of Science:

• Pharmaceutical Analysis
• Analytical Chemistry
• Quality Control

Background:

• Meprobamate is a widely used anxiolytic and sedative medication.
• Ensuring the purity of pharmaceutical products is critical for patient safety and drug efficacy.
• Impurities in drug formulations can arise from synthesis, degradation, or storage.

Purpose of the Study:

• To identify and quantify impurities in meprobamate raw material and finished tablet products.
• To characterize a specific known impurity and detect unknown impurities.
• To establish quality control parameters for meprobamate drug products.

Main Methods:

• Thin-layer chromatography (TLC) was employed for impurity profiling.
• Mass spectrometry (MS), Proton Magnetic Resonance (PMR), and Infrared (IR) spectroscopy were used for compound identification.
• Comparison with synthesized standards was performed for confirmation.

Main Results:

• All 28 lots of meprobamate tablets and one lot of raw material contained di-(2-methyl-2-propyl-3-carbamoyloxypropyl) carbonate (V) at 0.1–1.0%.
• Nine lots showed low levels (approx. 0.1%) of a second unidentified impurity.
• One lot contained a third unidentified impurity (approx. 0.1%).
• Compound V was definitively identified using spectroscopic methods and comparison with a synthesized sample.

Conclusions:

• The presence of di-(2-methyl-2-propyl-3-carbamoyloxypropyl) carbonate (V) is a common finding in meprobamate products.
• Further investigation is needed to identify the unknown impurities detected.
• These findings highlight the importance of rigorous analytical testing in pharmaceutical quality assurance.